A Cultural Gap: How Many Patients With Metastatic Pancreatic Cancer Do Not Start Systemic Therapy?

Different cultural approches between the Netherlands and the US.

Sep 6

19

3

“Chemo‑free” is not always better: the FDA withdrawal of adagrasib in colorectal cancer

We have all heard the powerful marketing phrases “chemo-free” and “targeted therapy.” They sound modern, precise, and less toxic.

Sep 4 • Sahar van Waalwijk

13

10

1

August 2026

Daraxonrasib Is FDA-Approved: Both Good News and Bad News

A key point is in the label: one part is a clear benefit for patients, the other raises far more questions.

Aug 27

25

3

Beyond Cross-Trial Comparisons: What Digitized Survival Curves Can Really Tell Us

In today’s guest post, it’s my great pleasure to welcome Yago Garitaonaindia and Marco Donia.

Aug 5 • Yago Garitaonaindia and Marco Donia

17

1

July 2026

Sham Controls and Tumor Treating Fields: Does the Ethical Argument Hold?

Our new paper published in the European Journal of Cancer highlight current limitations regarding the efficacy of TTFs in oncology.

Jul 11 • Sahar van Waalwijk and Timothée Olivier

14

1

EMA and FDA Advocate Removing Amgen’s Drug from the Market: How Unblinded Personnel Manipulated the ADVOCATE Trial

It’s my pleasure to welcome back Sahar Van Waalwijk, who covers an important topic following an unusual development.

Jul 9 • Sahar van Waalwijk

18

3

May 2026

Additional Insights Into Early Daraxonrasib Data

Let’s take a deep dive into the early-phase data on daraxonrasib in patients with metastatic pancreatic cancer, just published in the New England…

May 19

23

2

World-first tumour-agnostic reimbursement for dual immunotherapy (ipilimumab plus nivolumab), an academic debate, and the DART trial

In two back-to-back essays, we and our counterparts reach opposing conclusions regarding the DART trial and broad reimbursement of dual immunotherapy.

May 16 • Timothée Olivier and Sahar van Waalwijk

15

2

RASolute 302 (daraxonrasib) in metastatic pancreatic cancer: a revolution?

A pharmacological breakthrough might not always revolutionize patients' outcomes.

May 4 • Timothée Olivier

24

2

1

April 2026

An Eagle Eye on AQUILA Survival Data. Our New Paper Is Out. IQWiG Wins, OpenEvidence Fails.

Our new paper, with Sunny Kim and Vinay Prasad, is out in the Journal of Cancer Policy and is openly available here! Not all patients with Smoldering…

Apr 14 • Timothée Olivier

16

1

The Chinese Immunotherapy That Passed the Dutch Test, and How To Assess What is Expected to Be a Tsunami of Immunotherapies.

The Dutch are rather picky in selecting which oncology drugs to prescribe or reimburse.

Apr 12 • Sahar van Waalwijk and Timothée Olivier

24

3

March 2026

An outstanding source of trial data lacking from publications: IQWiG assessment reports. The NIAGARA trial example.

Reports from HTA bodies may contain key data absent from trial publications and constitute a unique source for trial appraisal.

Mar 25 • Timothée Olivier

14

2

1